Related Experiment Video
Updated: Aug 6, 2026
Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
Published on: July 7, 2023
Resting-state EEG biomarkers predict serotonin-norepinephrine reuptake inhibitor response in depression
Objective:
To develop an objective model using resting-state EEG biomarkers to predict individual response to serotonin-norepinephrine reuptake inhibitors (SNRIs) in depression, addressing the limitations of subjective traditional methods.
Methods:
Baseline resting-state EEG was recorded in 118 patients with depression. After data preprocessing, 26 patients were excluded (21 due to unusable EEG data and 5 due to missed follow-ups), leaving 92 patients for final analysis. Key predictive features identified were left temporal delta power spectral density (PSD), right temporal alpha-beta cross-frequency coupling (CFC), and occurrence of microstate D. A binary logistic regression model incorporating these features was built. A nomogram was developed for clinical use. Model validation used the area under the ROC curve (AUC), C-index, and clinical decision curve analysis (DCA).
Results:
The model demonstrated strong predictive power (AUC = 0.876; C-index = 0.876). DCA indicated significant clinical net benefit across decision thresholds. Key EEG features (PSD, CFC, microstate patterns) significantly differed between SNRI responders and non-responders.
Conclusions:
Resting-state EEG biomarkers provide a promising objective tool for predicting SNRI response, advancing precision medicine in depression treatment.
Significance:
This EEG-based model offers a novel, objective approach to personalize antidepressant selection, potentially improving treatment outcomes and efficiency over current subjective methods. Future integration with other neuroimaging could further enhance prediction.
